

## Rapid test for emergency evaluation of sepsis, 2/17

**February 2017**—Nanomix released a rapid diagnostic test panel designed to quickly evaluate patients affected by sepsis and that runs on Nanomix eLab, the company's handheld diagnostic system. Designed for emergency medical and other point-of-care needs, the test uses a single patient blood, plasma, or serum sample to provide actionable results within 10 minutes. The company said it plans to initiate formal clinical trials of the sepsis panel by mid-year and, if successful, will seek the CE mark and 510(k) approval by 2018.

"Our rapid sepsis panel, formatted into a disposable microfluidics test cartridge that the user inserts into our handheld eLab, incorporates enzymatic and immunoassays for three key sepsis markers. As such, it represents the first set of sepsis-related screening diagnostics that can be performed quickly at the first point of contact between a patient and the health care provider," David Ludvigson, Nanomix president and chief executive officer, said in a statement.

[\*\*Nanomix\*\*](#), 510-428-5300